Innovent’s Altruist BioLogics Receives China’s First Drug Manufacturing Approval for 80,000-Liter CDMO Facility, Expanding Total Capacity to 232,000 Liters

Altruist BioLogics, the contract development and manufacturing organization (CDMO) subsidiary of China’s Innovent, has received China’s first drug manufacturing approval for four 20,000-liter bioreactors, with a total capacity of 80,000 liters. The newly approved Hangzhou facility will handle the development and commercial manufacturing of antibodies, fusion proteins and antibody-drug conjugates (ADCs), with total production capacity reaching 172,000 liters upon completion. Including the existing 60,000-liter Suzhou facility, Altruist will secure total production capacity of 232,000 liters and plans to compete in the global CDMO market in earnest.